Drug Information

Drug General Information
Drug ID
D0E5BW
Former ID
DIB009553
Drug Name
[131I]-Metuximab injection
Drug Type
Antibody
Indication Liver cancer [ICD9: 140-229, 155, 203.0; ICD10:C22] Phase 2 [522539]
Company
Elsevier
Target and Pathway
Target(s) Basigin Target Info [528202]
Pathway Interaction Database Syndecan-1-mediated signaling events
Reactome Degradation of the extracellular matrix
Basigin interactions
Integrin cell surface interactions
Pyruvate metabolism
WikiPathways The citric acid (TCA) cycle and respiratory electron transport
Integrin cell surface interactions
Cell surface interactions at the vascular wall
Matrix Metalloproteinases
References
Ref 522539ClinicalTrials.gov (NCT00819650) A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection. U.S. National Institutes of Health.
Ref 528202Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):435-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.